Metastatic Colorectal Cancer (mCRC)
Oncology
2
Pipeline Programs
4
Companies
3
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 2 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
CytoDyn350 mg leronlimab
mAbxienceBevacizumab biosimilar
TakedaFruquintinib in Patients With Metastatic Colorectal Cancer
Clinical Trials (3)
Total enrollment: 352 patients across 3 trials
A Phase 2 Study of Leronlimab in Combination With TAS-102 + Bevacizumab in Previously Treated Participants With mCRC
Start: Jun 2025Est. completion: Mar 202860 patients
Phase 2Recruiting
Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients
Start: Oct 2014Est. completion: Jun 2017142 patients
Phase 1Completed
Fruquintinib in Patients With Metastatic Colorectal Cancer
Start: Feb 2025Est. completion: Dec 2027150 patients
N/ARecruiting
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
15m ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
15m ago
Office Administrator
SystImmune
15m ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
25m ago
Working Student Office Management Support (m/f/d)
Mindpeak
Hamburg
29m ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
29m ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 352 patients
4 companies competing in this space